These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 28688613)

  • 1. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
    Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
    King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
    Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brachytherapy boost for prostate cancer: Trends in care and survival outcomes.
    Glaser SM; Dohopolski MJ; Balasubramani GK; Benoit RM; Smith RP; Beriwal S
    Brachytherapy; 2017; 16(2):330-341. PubMed ID: 28159553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
    Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
    Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
    Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
    Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
    Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
    Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
    Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
    Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
    J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
    Morris WJ; Pickles T; Keyes M
    Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
    Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
    Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
    Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.